Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6119773,distribution half-life,"Following the i.v. dose, ranitidine plasma concentrations fell biexponentially with a distribution half-life of 6.1 +/- 0.9 min and a terminal elimination half-life of 1.9 +/- 0.1 h.",Pharmacokinetic and gastric secretory studies of ranitidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),min,6.1,260,DB00183,Pentagastrin
,6119773,terminal elimination half-life,"Following the i.v. dose, ranitidine plasma concentrations fell biexponentially with a distribution half-life of 6.1 +/- 0.9 min and a terminal elimination half-life of 1.9 +/- 0.1 h.",Pharmacokinetic and gastric secretory studies of ranitidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),h,1.9,261,DB00183,Pentagastrin
,6119773,volume of distribution,The volume of distribution was 115 +/- 7 1 and the systemic plasma clearance 709 +/- 62 ml/min.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),1,115,262,DB00183,Pentagastrin
,6119773,systemic plasma clearance,The volume of distribution was 115 +/- 7 1 and the systemic plasma clearance 709 +/- 62 ml/min.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),[ml] / [min],709,263,DB00183,Pentagastrin
,6119773,systemic availability,After 20 mg oral doses the systemic availability was high (88 +/- 10%).,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,88,264,DB00183,Pentagastrin
,6119773,Renal excretion,Renal excretion of unchanged ranitidine was between 50 and 70% and a further 1-3% was excreted as desmethylranitidine.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,50 and 70,265,DB00183,Pentagastrin
,6119773,Renal excretion,Renal excretion of unchanged ranitidine was between 50 and 70% and a further 1-3% was excreted as desmethylranitidine.,Pharmacokinetic and gastric secretory studies of ranitidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6119773/),%,1-3,266,DB00183,Pentagastrin
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,3.5,11466,DB00183,Pentagastrin
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,6.7,11467,DB00183,Pentagastrin
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,5.6,11468,DB00183,Pentagastrin
,31103048,gastric,"The observed pH values were significantly different among groups (p=0.0341), with the median (IQR) values of gastric pH of 3.5 (2.7-4.2), 6.7 (4.7-7.0), 5.6 (3.5-6.4) and 2.2 (1.6-3.1) in control, omeprazole 2 h, omeprazole 12 h and pentagastin group, respectively.",Gastric pH in Rats: Key Determinant for Preclinical Evaluation of pH-dependent Oral Drug Absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103048/),,2.2,11469,DB00183,Pentagastrin
,6299642,Elimination t 1/2,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),h,2,16380,DB00183,Pentagastrin
,6299642,plasma clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],10.4,16381,DB00183,Pentagastrin
,6299642,plasma clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],7.2,16382,DB00183,Pentagastrin
,6299642,renal clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],10.4,16383,DB00183,Pentagastrin
,6299642,hepatic clearance,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[ml] / [kg·min],10.4,16384,DB00183,Pentagastrin
,6299642,volume of distribution,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),[l] / [kg],1.82,16385,DB00183,Pentagastrin
,6299642,t 1/2,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),h,2.7,16386,DB00183,Pentagastrin
,6299642,bioavailability,"Elimination t 1/2, plasma clearance, renal clearance, hepatic clearance, and volume of distribution for ranitidine after intravenous injection were 2 hr, 10.4 ml/(min X kg), 7.2 ml/(min X kg), 3.1 ml/(min X kg), and 1.82 l/kg, respectively; after oral doses mean t 1/2 was 2.7 hr and mean bioavailability was 52%.",Ranitidine bioavailability and kinetics in normal male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),%,52,16387,DB00183,Pentagastrin
,6299642,cumulative urinary excretion,The average cumulative urinary excretion of ranitidine as percent of dose was 69.4 +/- 6.1% and 26.7 +/- 7.2% after intravenous and oral doses.,Ranitidine bioavailability and kinetics in normal male subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),%,69.4,16388,DB00183,Pentagastrin
,6299642,cumulative urinary excretion,The average cumulative urinary excretion of ranitidine as percent of dose was 69.4 +/- 6.1% and 26.7 +/- 7.2% after intravenous and oral doses.,Ranitidine bioavailability and kinetics in normal male subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6299642/),%,26.7,16389,DB00183,Pentagastrin
,1294333,gastric emptying time,"Here, the gastric acidity, the gastric emptying time and the small intestinal transit time in the regulated-dogs were respectively around pH 2, 0.7h and 4h, approximating those in healthy humans.",Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294333/),h,0.7,48203,DB00183,Pentagastrin
,1294333,small intestinal transit time,"Here, the gastric acidity, the gastric emptying time and the small intestinal transit time in the regulated-dogs were respectively around pH 2, 0.7h and 4h, approximating those in healthy humans.",Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1294333/),h,4,48204,DB00183,Pentagastrin
,16806752,AUC(0-->96),"The area under the meloxicam plasma concentration-time curve (AUC(0-->96)(h) was not significantly different between the two preparations (p>0.05), although AUC(0-->96)(h) obtained after oral administration of coated pellets (142.5+/-59.6 microg h/ml) was lower than that obtained after administration of uncoated drug-layered cores (180.8+/-61.9 microg h/ml).",In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806752/),[h·μg] / [ml],142.5,60745,DB00183,Pentagastrin
,16806752,AUC(0-->96),"The area under the meloxicam plasma concentration-time curve (AUC(0-->96)(h) was not significantly different between the two preparations (p>0.05), although AUC(0-->96)(h) obtained after oral administration of coated pellets (142.5+/-59.6 microg h/ml) was lower than that obtained after administration of uncoated drug-layered cores (180.8+/-61.9 microg h/ml).",In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806752/),[h·μg] / [ml],180.8,60746,DB00183,Pentagastrin
,9517952,terminal half-life,The concentrations of PMPA in plasma after intravenous injection were best described by an open two-compartment model with a terminal half-life of approximately 10 h.,Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517952/),h,10,64998,DB00183,Pentagastrin
,9517952,recovery,PMPA was excreted unchanged in urine (70%); recovery in feces (0.42%) or bile (0.26%) was negligible.,Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517952/),%,0.42,64999,DB00183,Pentagastrin
,9517952,recovery,PMPA was excreted unchanged in urine (70%); recovery in feces (0.42%) or bile (0.26%) was negligible.,Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517952/),%,0.26,65000,DB00183,Pentagastrin
,9517952,plasma clearance,"The plasma clearance of PMPA (0.28+/-0.05 liter/h/kg) was substantially greater than the glomerular filtration rate in this species, suggesting active tubular secretion of PMPA.",Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517952/),[l] / [h·kg],0.28,65001,DB00183,Pentagastrin
,9517952,observed,"The mean+/-standard deviation observed bioavailabilities of PMPA following oral and intraperitoneal administration at 10 mg/kg were 17.1%+/-1.88% and 73.5%+/-10.5%, respectively.",Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517952/),%,17.1,65002,DB00183,Pentagastrin
,9517952,bioavailabilities,"The mean+/-standard deviation observed bioavailabilities of PMPA following oral and intraperitoneal administration at 10 mg/kg were 17.1%+/-1.88% and 73.5%+/-10.5%, respectively.",Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517952/),%,17.1,65003,DB00183,Pentagastrin
,9517952,bioavailabilities,"The mean+/-standard deviation observed bioavailabilities of PMPA following oral and intraperitoneal administration at 10 mg/kg were 17.1%+/-1.88% and 73.5%+/-10.5%, respectively.",Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517952/),%,73.5,65004,DB00183,Pentagastrin
,3147901,metabolic clearance rate,The metabolic clearance rate was 5.2 +/- 0.7 ml kg-1 min-1 and the half-life in plasma was 12 +/- 1 min.,Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147901/),[ml] / [kg·min],5.2,71873,DB00183,Pentagastrin
,3147901,half-life,The metabolic clearance rate was 5.2 +/- 0.7 ml kg-1 min-1 and the half-life in plasma was 12 +/- 1 min.,Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147901/),min,12,71874,DB00183,Pentagastrin
,11136283,terminal disposition half-life,Lansoprazole's terminal disposition half-life was 1.11 h.,Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,1.11,98778,DB00183,Pentagastrin
,11136283,half-lives,"Mean pH and serum gastrin returned to baseline with half-lives of 22 and 19 h, respectively.",Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,22,98779,DB00183,Pentagastrin
,11136283,half-lives,"Mean pH and serum gastrin returned to baseline with half-lives of 22 and 19 h, respectively.",Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136283/),h,19,98780,DB00183,Pentagastrin
,2714145,metabolic clearance rate (MCR),"The metabolic clearance rate (MCR) of GLP-1 was 2.2 +/- 0.3 and 2.6 +/- 0.3 ml/kg/min, respectively, and the half-life in plasma was 17 +/- 2 min.","GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714145/),[ml] / [kg·min],2.2,110893,DB00183,Pentagastrin
,2714145,metabolic clearance rate (MCR),"The metabolic clearance rate (MCR) of GLP-1 was 2.2 +/- 0.3 and 2.6 +/- 0.3 ml/kg/min, respectively, and the half-life in plasma was 17 +/- 2 min.","GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714145/),[ml] / [kg·min],2.6,110894,DB00183,Pentagastrin
,2714145,half-life,"The metabolic clearance rate (MCR) of GLP-1 was 2.2 +/- 0.3 and 2.6 +/- 0.3 ml/kg/min, respectively, and the half-life in plasma was 17 +/- 2 min.","GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714145/),min,17,110895,DB00183,Pentagastrin
,2714145,MCR,The MCR of truncated GLP-1 was 13 +/- 2.8 ml/kg/min and the half-life 11.4 +/- 2.1 min.,"GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714145/),[ml] / [kg·min],13,110896,DB00183,Pentagastrin
,2714145,half-life,The MCR of truncated GLP-1 was 13 +/- 2.8 ml/kg/min and the half-life 11.4 +/- 2.1 min.,"GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714145/),min,11.4,110897,DB00183,Pentagastrin
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,22,111807,DB00183,Pentagastrin
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,63,111808,DB00183,Pentagastrin
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,78,111809,DB00183,Pentagastrin
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,56,111810,DB00183,Pentagastrin
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,97,111811,DB00183,Pentagastrin
,2177296,percent inhibition,"Repeated once-daily infusion (15 min) of pantoprazole resulted in a rapidly increasing pharmacodynamic effect: as compared to placebo the mean percent inhibition of acid output measured from 1 to 3 h after start of infusion was 22%, 63% and 78% for the 15 mg dose, and 56%, 97% and 99% for the 30 mg dose on days 1, 4 and 5, respectively.","Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2177296/),%,99,111812,DB00183,Pentagastrin
,21493750,pK(I),"JNJ-26070109 expressed high affinity for human (pK(I) = 8.49 ± 0.13), rat (pK(I) = 7.99 ± 0.08), and dog (pK(I) = 7.70 ± 0.14) CCK2 receptors.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,8.49,111862,DB00183,Pentagastrin
,21493750,pK(I),"JNJ-26070109 expressed high affinity for human (pK(I) = 8.49 ± 0.13), rat (pK(I) = 7.99 ± 0.08), and dog (pK(I) = 7.70 ± 0.14) CCK2 receptors.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,7.99,111863,DB00183,Pentagastrin
,21493750,pK(I),"JNJ-26070109 expressed high affinity for human (pK(I) = 8.49 ± 0.13), rat (pK(I) = 7.99 ± 0.08), and dog (pK(I) = 7.70 ± 0.14) CCK2 receptors.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,7.70,111864,DB00183,Pentagastrin
,21493750,pK(B),"JNJ-26070109 behaved as a surmountable, competitive, antagonist of human CCK2 receptors in a calcium mobilization assay (pK(B) = 8.53 ± 0.05) and in pentagastrin-stimulated gastric acid secretion in the isolated, lumen-perfused, mouse stomach assay (pK(B) = 8.19 ± 0.13).","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,8.53,111865,DB00183,Pentagastrin
,21493750,p,"JNJ-26070109 behaved as a surmountable, competitive, antagonist of human CCK2 receptors in a calcium mobilization assay (pK(B) = 8.53 ± 0.05) and in pentagastrin-stimulated gastric acid secretion in the isolated, lumen-perfused, mouse stomach assay (pK(B) = 8.19 ± 0.13).","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,8.19,111866,DB00183,Pentagastrin
,21493750,%F,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),,73,111867,DB00183,Pentagastrin
,21493750,%F,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),h,92,111868,DB00183,Pentagastrin
,21493750,half lives,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),h,1.8,111869,DB00183,Pentagastrin
,21493750,half lives,"JNJ-26070109 was shown to have high oral bioavailability (%F rat = 73 ± 16; %F dog = 92 ± 12) with half lives of 1.8 ± 0.3 and 1.2 ± 0.1 h in rat and dog, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),h,1.2,111870,DB00183,Pentagastrin
,21493750,oral EC(50),"In conscious rat and dog chronic gastric fistula models of pentagastrin-stimulated acid secretion, JNJ-26070109 had oral EC(50) values of 1.5 and 0.26 μM, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),μM,1.5,111871,DB00183,Pentagastrin
,21493750,oral EC(50),"In conscious rat and dog chronic gastric fistula models of pentagastrin-stimulated acid secretion, JNJ-26070109 had oral EC(50) values of 1.5 and 0.26 μM, respectively.","JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21493750/),μM,0.26,111872,DB00183,Pentagastrin
,8100500,recoveries,"After iv dose, 87% and 0.5% of the administered radioactivity were recovered in urine and feces within 6 days, respectively; the corresponding recoveries were 84% and 2.1% after po dose.","Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100500/),%,84,117731,DB00183,Pentagastrin
,8100500,recoveries,"After iv dose, 87% and 0.5% of the administered radioactivity were recovered in urine and feces within 6 days, respectively; the corresponding recoveries were 84% and 2.1% after po dose.","Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100500/),%,2.1,117732,DB00183,Pentagastrin
,8100500,absolute bioavailability,"Oral absorption of didanosine was rapid and complete; but due to first pass metabolism, the absolute bioavailability of didanosine was 44%.","Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100500/),%,44,117733,DB00183,Pentagastrin
,8100500,renal clearance,Mean renal clearance of didanosine (110 ml/min) accounted for about 43% of the total body clearance.,"Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100500/),[ml] / [min],110,117734,DB00183,Pentagastrin
,8100500,steady state volume of distribution,The mean steady state volume of distribution of didanosine was 9.6 liters.,"Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100500/),l,9.6,117735,DB00183,Pentagastrin
,8100500,terminal half-life,The mean terminal half-life of didanosine was 0.8 hr after iv or po administration.,"Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100500/),h,0.8,117736,DB00183,Pentagastrin
,6679515,peak plasma concentration,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [ml],2.13,132195,DB00183,Pentagastrin
,6679515,peak plasma concentration,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [ml],1.43,132196,DB00183,Pentagastrin
,6679515,area under the plasma concentration curve (A.U.C.) between 0 to 8 hours,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [h·ml],8.49,132197,DB00183,Pentagastrin
,6679515,area under the plasma concentration curve (A.U.C.) between 0 to 8 hours,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),[μg] / [h·ml],5.83,132198,DB00183,Pentagastrin
,6679515,time span,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),min,401,132199,DB00183,Pentagastrin
,6679515,time span,"The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy.",Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6679515/),min,296,132200,DB00183,Pentagastrin
greater,25720462,AUC ratios,"The AUC ratios of omeprazole and erythromycin, which are administered orally to humans, as enteric-coated tablets, were greater than 1.9 in the rats and dogs controlled for gastric acid secretion.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.9,135783,DB00183,Pentagastrin
less,25720462,AUC ratios,"On the contrary, the AUC ratios of clarithromycin, azithromycin, and etoposide (commercially available as a standard immediate-release form) were less than 1.3 each.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.3,135784,DB00183,Pentagastrin
,32535897,binding constant,"The in vitro binding constant between fenebrutinib and hydroxypropyl-β-cyclodextrin was determined to be 2 × 105 M-1 , and the apparent permeability of fenebrutinib across a Madin-Darby canine kidney cell monolayer decreased in a cyclodextrin concentration-dependent manner.",Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32535897/),1/[M],2 × 105,139069,DB00183,Pentagastrin
,11210394,half-lives,Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans.,Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),h,0.5,160213,DB00183,Pentagastrin
,11210394,half-lives,Pantoprazole has short half-lives of 0.5 hours in rats and 0.8 hours in humans.,Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),h,0.8,160214,DB00183,Pentagastrin
,11210394,apparent reaction rate constants,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),[l] / [h·mg],0.691,160215,DB00183,Pentagastrin
,11210394,apparent reaction rate constants,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),[l] / [h·mg],0.751,160216,DB00183,Pentagastrin
,11210394,apparent recovery rates,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),1/[h],0.053,160217,DB00183,Pentagastrin
,11210394,apparent recovery rates,"The apparent reaction rate constants of pantoprazole with the proton pumps were 0.691 L/mg/h in rats and 0.751 L/mg/h in humans, and the apparent recovery rates of the pumps were 0.053 h-1 and 0.031 h-1, respectively.",Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210394/),1/[h],0.031,160218,DB00183,Pentagastrin
,1747504,half-life,"After each bolus, the time course of serum concentration was described by a single exponential, yielding an estimation of caffeine half-life: 310 +/- 46 (n = 9) and 453 +/- 59 min (n = 9), respectively.",Investigations on caffeine passage into the canine gastric juice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747504/),min,310,177415,DB00183,Pentagastrin
,1747504,half-life,"After each bolus, the time course of serum concentration was described by a single exponential, yielding an estimation of caffeine half-life: 310 +/- 46 (n = 9) and 453 +/- 59 min (n = 9), respectively.",Investigations on caffeine passage into the canine gastric juice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747504/),min,453,177416,DB00183,Pentagastrin
,1747504,apparent volume of distribution,In both cases the same apparent volume of distribution: 0.87 +/- 0.02 l/kg (n = 9) was found.,Investigations on caffeine passage into the canine gastric juice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747504/),[l] / [kg],0.87,177417,DB00183,Pentagastrin
,7864254,EBF,"By use of this technique, baseline EBF and MBF were 37.8 +/- 3.53 (n = 21) and 47.2 +/- 4.56 (n = 5) ml.min-1.100 g-1, respectively, with an EBF/MBF ratio of 0.8.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),[ml] / [g·min],37.8,185358,DB00183,Pentagastrin
,7864254,MBF,"By use of this technique, baseline EBF and MBF were 37.8 +/- 3.53 (n = 21) and 47.2 +/- 4.56 (n = 5) ml.min-1.100 g-1, respectively, with an EBF/MBF ratio of 0.8.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),[ml] / [g·min],47.2,185359,DB00183,Pentagastrin
,7864254,EBF/MBF ratio,"By use of this technique, baseline EBF and MBF were 37.8 +/- 3.53 (n = 21) and 47.2 +/- 4.56 (n = 5) ml.min-1.100 g-1, respectively, with an EBF/MBF ratio of 0.8.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),,0.8,185360,DB00183,Pentagastrin
,7864254,EBF/MBF ratio,"With the iodo[14C]antipyrine technique, the EBF/MBF ratio was 0.91 +/- 0.07 (n = 5), which is similar to that obtained with the H2 gas clearance technique.",H2 gas clearance technique for separating rat uterine blood flow into endometrial and myometrial components. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7864254/),,0.91,185361,DB00183,Pentagastrin
,8617118,concentration area under the curve (AUC),Omeprazole reduced mean pentagastrin-stimulated peak gastric acid secretion by 85.5% +/- 23.7% when delivered orally and by 79.6% +/- 32.1% when delivered by nasogastric tube; the mean plasma omeprazole concentration area under the curve (AUC) was 2.02 +/- 0.79 after oral delivery and 1.74 +/- 1.89 after nasogastric tube delivery.,Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617118/),,2.02,188110,DB00183,Pentagastrin
,8617118,concentration area under the curve (AUC),Omeprazole reduced mean pentagastrin-stimulated peak gastric acid secretion by 85.5% +/- 23.7% when delivered orally and by 79.6% +/- 32.1% when delivered by nasogastric tube; the mean plasma omeprazole concentration area under the curve (AUC) was 2.02 +/- 0.79 after oral delivery and 1.74 +/- 1.89 after nasogastric tube delivery.,Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8617118/),,1.74,188111,DB00183,Pentagastrin
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,76,189383,DB00183,Pentagastrin
,8000380,bioavailability,"The bioavailability of the SR tablet accounted for 76% in the regulated-dogs and 71% in intact dogs relative to that of the conventional tablet in the regulated-dogs, respectively, but no significant difference was detectable between these values.",Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8000380/),%,71,189384,DB00183,Pentagastrin
,6305671,t1/2 beta,"The drug followed a two-compartment model, with mean values for t1/2 beta, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively.",The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),min,80,190251,DB00183,Pentagastrin
,6305671,volume of distribution steady-state,"The drug followed a two-compartment model, with mean values for t1/2 beta, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively.",The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),[ml] / [min],701,190252,DB00183,Pentagastrin
,6305671,total plasma clearance,"The drug followed a two-compartment model, with mean values for t1/2 beta, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively.",The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),[ml] / [min],680,190253,DB00183,Pentagastrin
,6305671,oral bioavailability,The oral bioavailability of ranitidine in these 5 patients showed wide variation (27-76%; mean 51%).,The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: a comparison of responders and non-responders. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6305671/),%,51,190254,DB00183,Pentagastrin
,6413241,plateau plasma levels,"PHI, infused in man, achieved plateau plasma levels of 297 pmoles/1.","Infusion of a novel peptide, PHI, in man. Pharmacokinetics and effect on gastric secretion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6413241/),,29,197312,DB00183,Pentagastrin
,6413241,plasma half life,"The plasma half life was 3.1 min, metabolic clearance rate was 16.4 ml/kg/min and estimated volume of distribution was 73.2 ml/kg.","Infusion of a novel peptide, PHI, in man. Pharmacokinetics and effect on gastric secretion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6413241/),min,3.1,197313,DB00183,Pentagastrin
,6413241,metabolic clearance rate,"The plasma half life was 3.1 min, metabolic clearance rate was 16.4 ml/kg/min and estimated volume of distribution was 73.2 ml/kg.","Infusion of a novel peptide, PHI, in man. Pharmacokinetics and effect on gastric secretion. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6413241/),[ml] / [kg·min],16.4,197314,DB00183,Pentagastrin
,6413241,volume of distribution,"The plasma half life was 3.1 min, metabolic clearance rate was 16.4 ml/kg/min and estimated volume of distribution was 73.2 ml/kg.","Infusion of a novel peptide, PHI, in man. Pharmacokinetics and effect on gastric secretion. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6413241/),[ml] / [kg],73.2,197315,DB00183,Pentagastrin
,9423141,oral bioavailability,The oral bioavailability of adefovir from the suspension was 35.0 +/- 8.9%.,Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423141/),%,35.0,209699,DB00183,Pentagastrin
,9423141,oral bioavailability,"The oral bioavailability of adefovir from the tablet formulation was 34.7 +/- 10.3%, 37.2 +/- 4.5%, and 44.9 +/- 5.9% in fasted dogs, fed dogs and fasted dogs pretreated with pentagastrin, respectively.",Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423141/),%,34.7,209700,DB00183,Pentagastrin
,9423141,oral bioavailability,"The oral bioavailability of adefovir from the tablet formulation was 34.7 +/- 10.3%, 37.2 +/- 4.5%, and 44.9 +/- 5.9% in fasted dogs, fed dogs and fasted dogs pretreated with pentagastrin, respectively.",Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423141/),%,37.2,209701,DB00183,Pentagastrin
,9423141,oral bioavailability,"The oral bioavailability of adefovir from the tablet formulation was 34.7 +/- 10.3%, 37.2 +/- 4.5%, and 44.9 +/- 5.9% in fasted dogs, fed dogs and fasted dogs pretreated with pentagastrin, respectively.",Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423141/),%,44.9,209702,DB00183,Pentagastrin
,9423141,Oral bioavailability,"Oral bioavailability of adefovir from the prodrug in dogs (35-46%) was unaffected by formulation, food, or the acidic pH of the gastrointestinal tract.",Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423141/),%,35-46,209703,DB00183,Pentagastrin
,6105117,elimination half-life,The estimated elimination half-life was 140 minutes and the bioavailability of the oral drug was about 50%.,Ranitidine--a new H2-receptor antagonist. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105117/),min,140,214329,DB00183,Pentagastrin
,6105117,bioavailability,The estimated elimination half-life was 140 minutes and the bioavailability of the oral drug was about 50%.,Ranitidine--a new H2-receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105117/),%,50,214330,DB00183,Pentagastrin
exceeded,2892261,absolute oral bioavailability,"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),%,90,215101,DB00183,Pentagastrin
,2892261,half-life (t1/2),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),h,1.3,215102,DB00183,Pentagastrin
,2892261,plasma clearance (Clp),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),1/[h],461,215103,DB00183,Pentagastrin
,2892261,volume of distribution (Vd),"The absolute oral bioavailability of nizatidine exceeded 90%; the half-life (t1/2), plasma clearance (Clp), and volume of distribution (Vd) of iv nizatidine were 1.3 h, 461/h, and 1.21/kg, respectively.",A pharmacokinetic profile of nizatidine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892261/),1/[kg],1.21,215104,DB00183,Pentagastrin
,16435487,concentrations,"Mean plasma VIP concentrations rose from 5.7 pmol/l to 28, 106 and 336 pmol/l during the VIP infusions.",Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),[pM] / [l],5.7,224002,DB00183,Pentagastrin
,16435487,concentrations,"Mean plasma VIP concentrations rose from 5.7 pmol/l to 28, 106 and 336 pmol/l during the VIP infusions.",Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),[pM] / [l],28,224003,DB00183,Pentagastrin
,16435487,concentrations,"Mean plasma VIP concentrations rose from 5.7 pmol/l to 28, 106 and 336 pmol/l during the VIP infusions.",Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),[pM] / [l],106,224004,DB00183,Pentagastrin
,16435487,concentrations,"Mean plasma VIP concentrations rose from 5.7 pmol/l to 28, 106 and 336 pmol/l during the VIP infusions.",Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),[pM] / [l],336,224005,DB00183,Pentagastrin
,16435487,half-lives,"Elimination of VIP was bi-exponential with half-lives of 2 and 21 min, respectively.",Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),min,2,224006,DB00183,Pentagastrin
,16435487,half-lives,"Elimination of VIP was bi-exponential with half-lives of 2 and 21 min, respectively.",Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),min,21,224007,DB00183,Pentagastrin
,16435487,Metabolic clearance rate,Metabolic clearance rate was 42 ml/kg-min and the estimated volume of distribution 135 ml/kg.,Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),[ml] / [kg-min],42,224008,DB00183,Pentagastrin
,16435487,volume of distribution,Metabolic clearance rate was 42 ml/kg-min and the estimated volume of distribution 135 ml/kg.,Infusion of vasoactive intestinal polypeptide in man: pharmacokinetics and effect on gastric acid secretion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435487/),[ml] / [kg],135,224009,DB00183,Pentagastrin
,16435489,half-lives,"Elimination of 15-LSG was bi-exponential, with half-lives of 5.2 +/- 0.8 and 25.9 +/- 7.0 min.",Acid secretory potency and elimination of the 15-leucine gastrin-17 analogue in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435489/),min,5.2,225344,DB00183,Pentagastrin
,16435489,half-lives,"Elimination of 15-LSG was bi-exponential, with half-lives of 5.2 +/- 0.8 and 25.9 +/- 7.0 min.",Acid secretory potency and elimination of the 15-leucine gastrin-17 analogue in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435489/),min,25.9,225345,DB00183,Pentagastrin
,16435489,Metabolic clearance rate,Metabolic clearance rate was 6.9 +/- 0.4 ml/kg-min and volume of distribution 52 ml/kg.,Acid secretory potency and elimination of the 15-leucine gastrin-17 analogue in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435489/),[ml] / [kg-min],6.9,225346,DB00183,Pentagastrin
,16435489,volume of distribution,Metabolic clearance rate was 6.9 +/- 0.4 ml/kg-min and volume of distribution 52 ml/kg.,Acid secretory potency and elimination of the 15-leucine gastrin-17 analogue in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16435489/),[ml] / [kg],52,225347,DB00183,Pentagastrin
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,15,231478,DB00183,Pentagastrin
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,29,231479,DB00183,Pentagastrin
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,46,231480,DB00183,Pentagastrin
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,28,231481,DB00183,Pentagastrin
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,62,231482,DB00183,Pentagastrin
,11563995,inhibition,"The mean inhibition values of the pentagastrin-stimulated peak acid output on day 1 for 5, 10 and 20 mg of esomeprazole were 15%, 29% and 46%, respectively; the corresponding day 5 values were 28%, 62% and 90%.","Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),%,90,231483,DB00183,Pentagastrin
,11563995,inhibition,The mean inhibition values of the pentagastrin-stimulated peak acid output for omeprazole were 35% (day 1) to 79% (day 5).,"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),,35,231484,DB00183,Pentagastrin
,11563995,inhibition,The mean inhibition values of the pentagastrin-stimulated peak acid output for omeprazole were 35% (day 1) to 79% (day 5).,"Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563995/),,79,231485,DB00183,Pentagastrin
,9821653,t 1/2 beta (elimination half-life),"The rate of degradation of deramciclane increased ten-fold as the pH was reduced from 2.1 to 1.2 (t 1/2 beta (elimination half-life) 9 h and 39 min, respectively).",Different absorption profiles of deramciclane in man and in dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821653/),h,9,247410,DB00183,Pentagastrin
,9821653,t 1/2 beta (elimination half-life),"The rate of degradation of deramciclane increased ten-fold as the pH was reduced from 2.1 to 1.2 (t 1/2 beta (elimination half-life) 9 h and 39 min, respectively).",Different absorption profiles of deramciclane in man and in dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821653/),min,39,247411,DB00183,Pentagastrin
,9821653,relative bioavailability,"In man the mean relative bioavailability and Cmax (peak plasma concentration) for the conventional capsules were approximately 75% and 83% of those for the enteric coated tablets (P = 0.0004 and P = 0.0031, respectively).",Different absorption profiles of deramciclane in man and in dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821653/),%,75,247412,DB00183,Pentagastrin
,9821653,Cmax (peak plasma concentration),"In man the mean relative bioavailability and Cmax (peak plasma concentration) for the conventional capsules were approximately 75% and 83% of those for the enteric coated tablets (P = 0.0004 and P = 0.0031, respectively).",Different absorption profiles of deramciclane in man and in dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9821653/),%,83,247413,DB00183,Pentagastrin
,3922013,plasma half-life,The plasma half-life of immunoreactive CGRP was calculated as 6.9 +/- 0.9 min for the fast decay and 26.4 +/- 4.7 min for the slow decay.,"Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922013/),min,6.9,248025,DB00183,Pentagastrin
,3922013,plasma half-life,The plasma half-life of immunoreactive CGRP was calculated as 6.9 +/- 0.9 min for the fast decay and 26.4 +/- 4.7 min for the slow decay.,"Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922013/),min,26.4,248026,DB00183,Pentagastrin
,3922013,MCR,The calculated MCR was 11.3 +/- 1.2 ml/kg per min.,"Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922013/),[ml] / [kg·min],11.3,248027,DB00183,Pentagastrin
,9701531,t1/2,The pharmacokinetics of rabeprazole were similar to those of other proton pump inhibitors with a t1/2 of between 0.7 and 1.0 h.,An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701531/),h,0.7 and 1.0,250659,DB00183,Pentagastrin
,7650224,EC50,The plasma concentration of famotidine associated with 50% inhibition of pentagastrin stimulated gastric acid secretion (EC50; 10 ng/mL) was attained on average within 0.5 hours post-dose for the wafer and tablet.,Novel oral medication delivery system for famotidine. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650224/),[ng] / [ml],10,259307,DB00183,Pentagastrin
,7911441,elimination half life,The elimination half life is about 1.5 hours and about 32% of a subcutaneous dose is excreted in the urine as unchanged octreotide.,Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7911441/),h,1.5,263089,DB00183,Pentagastrin
,7104188,solubility,The solubility of frusemide was significantly higher in gastric juice from two fasting subjects (83-104 mg l-1) than in buffer solutions with the same pH (52-58 mg 1-1).,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),[mg] / [l],83-104,264484,DB00183,Pentagastrin
,7104188,solubility,The solubility of frusemide was significantly higher in gastric juice from two fasting subjects (83-104 mg l-1) than in buffer solutions with the same pH (52-58 mg 1-1).,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),mg,52-58,264485,DB00183,Pentagastrin
,7104188,binding,The binding of frusemide to macromolecules was 28.0 +/- 9.7% in ventricular secretion after fasting while it was 1.4 +/- 2.6% in the fluid obtained after pentagastrin stimulation.,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),%,28.0,264486,DB00183,Pentagastrin
,7104188,binding,The binding of frusemide to macromolecules was 28.0 +/- 9.7% in ventricular secretion after fasting while it was 1.4 +/- 2.6% in the fluid obtained after pentagastrin stimulation.,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),%,1.4,264487,DB00183,Pentagastrin
,23980865,gastric pH,The average gastric pH in fasted dogs ranged from 1.45 to 3.03.,Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23980865/),,1.45 to 3.03,265403,DB00183,Pentagastrin
